Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences:
聖地亞哥，2024年11月26日，普新聞通社/ - Regulus Therapeutics Inc.（納斯達克：RGLS）是一家專注於發現和開發靶向microRNA的創新藥物的生物製藥公司（"公司"或"Regulus"），今天宣佈公司將參加以下投資者會議:
- Evercore 7th Annual HealthCONx Conference: Fireside chat on Tuesday, December 3, 2024, at 3:50 p.m. ET
- Piper Sandler 36th Annual Healthcare Conference: Presentation on Wednesday, December 4, 2024, at 11:10 a.m. ET
- Evercore第七屆年度HealthCONx會議：關於2024年12月3日星期二下午3:50的爐邊聊天
- 派傑投資第36屆年度醫療保健會議：關於2024年12月4日星期三上午11:10的演講
The live events and replays of the presentations will be available under "Events and Presentations" through the investor relations section of the Company's website at and archived for 90 days following the presentation date.
演講活動和演講重播將在公司網站的投資者關係部門的「事件和演講」下提供，並在演講日期後的90天內存檔。
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.
Regulus Therapeutics股份有限公司（納斯達克代碼：RGLS）是一家專注於發現和開發以微RNAs爲靶點的創新藥物的生物製藥公司。Regulus利用其寡核苷酸藥物發現和開發專業知識來開發一系列流水線，並在微RNA領域擁有豐富的知識產權。Regulus總部設在加利福尼亞州聖地亞哥。
Regulus Therapeutics Inc.（納斯達克：RGLS）是一家專注於發現和開發靶向microRNAs的創新藥物的生物製藥公司。Regulus擁有寡核苷酸藥物發現和開發方面的專業知識，已經在microRNA領域開發了一系列藥物並擁有豐富的知識產權。Regulus總部位於加利福尼亞州聖迭戈。
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program and preclinical pipeline, the potential that RGLS8429 may be eligible for an Accelerated Approval pathway, potentially achieving therapeutic efficacy and clinical translation for patients, the expected timing for reporting interim or topline data, and the timing and future occurrence of other preclinical and clinical activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that the approach we are taking to discover and develop drugs is novel and may never lead to marketable products, that preliminary or topline results are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and may not be indicative of future results, the FDA has not designated RGLS8429 for an Accelerated Approval pathway and such designation may not lead to a faster development, regulatory review or approval process and does not increase the likelihood that RGLS8429 will receive marketing approval, the risk that preclinical and clinical studies may not be successful, risks related to regulatory review and approval, risks related to our reliance on third-party collaborators and other third parties, risks related to intellectual property, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, the risk that additional toxicology data may be negative, and risks related to our ability to successfully secure and deploy capital. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus' quarterly report on Form 10-Q available on the Company's website or at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
前瞻性聲明
本新聞稿中關於非歷史事實的陳述是根據1995年《私人證券訴訟改革法》的定義的「前瞻性陳述」，包括與公司的RGLS8429項目和臨床前管線，RGLS8429有可能符合加快批准途徑、可能實現治療療效併爲患者帶來臨床轉化、預計報告中期或前線數據的時間以及未來臨床前和臨床活動的時間和發生的相關陳述。由於此類陳述存在風險和不確定性，實際結果可能與此類前瞻性陳述所表達或暗示的結果有所不同。我們希望通過「believes,」 「anticipates,」 「plans,」 「expects,」 「intends,」 「will,」 「goal,」 「potential」和類似表述來識別前瞻性陳述。這些前瞻性陳述基於Regulus目前的期望，並涉及可能從不會出現或可能證明是不正確的假設。實際結果和事件的時間可能與此類前瞻性陳述所預期的結果和事件的時間有所不同，這是由於各種風險和不確定性引起的，包括但不限於我們所採用的發現和開發藥物的方法是新穎的，可能永遠不會導致可銷售的產品，初步或前線結果是基於關鍵療效和安全數據的初步分析，並且在關於臨床試驗的數據進行更全面的審查之後，這些數據可能發生變化並且可能不具有未來結果的指示性，FDA並未爲RGLS8429指定加速批准途徑，並且該指定可能不會導致更快的開發，監管審查或批准流程，並且不會增加RGLS8429獲得上市許可的可能性，臨床前和臨床研究可能不會成功，與監管審查和批准相關的風險，與我們依賴第三方合作伙伴和其他第三方相關的風險，與知識產權相關的風險，與作爲人類治療藥物安全有效的發現、開發和商業化過程相關的風險，額外的毒理學數據可能是負面的風險，以及我們成功獲得和使用資本的能力相關的風險。上述風險和其他風險在Regulus向美國證券交易委員會提交的文件中有更詳細的描述，包括在Regulus的網站或www.sec.gov上可獲取的Regulus季度報告10-Q的「風險因素」部分。本新聞稿中包含的所有前瞻性陳述只是在其發表之日起的陳述。Regulus不承諾對此類陳述進行更新，以反映發生或存在於其發表之日之後的事件。
SOURCE Regulus Therapeutics Inc.
Regulus Therapeutics股份有限公司資訊來源。
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
